Charles Schwab Investment Management Inc Outlook Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$0.2 - $1.78 $12,499 - $111,241	-62,495 Reduced 14.98%	354,615 $78,000
Q2 2023 Aug 09, 2023	BUY	$1.02 - $1.89 $4,933 - $9,141	4,837 Added 1.17%	417,110 $725,000
Q1 2023 May 11, 2023	BUY	$1.0 - $1.35 $83,018 - $112,074	83,018 Added 25.21%	412,273 $449,000
Q3 2022 Nov 14, 2022	SELL	$1.02 - $1.26 $1,756 - $2,169	-1,722 Reduced 0.52%	329,255 $402,000
Q2 2022 Aug 15, 2022	BUY	$0.91 - $2.01 $13,001 - $28,716	14,287 Added 4.51%	330,977 $338,000

Q1 2022 May 13, 2022	BUY	$1.22 - $2.03 $117,881 - $196,146	96,624 Added 43.91%	316,690 $564,000
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $330,421 - $512,338	185,630 Added 539.06%	220,066 $548,000
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $32,369 - $113,983	34,436 New	34,436 $78,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.6B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.